JP2000515374A5 - - Google Patents

Download PDF

Info

Publication number
JP2000515374A5
JP2000515374A5 JP1998506830A JP50683098A JP2000515374A5 JP 2000515374 A5 JP2000515374 A5 JP 2000515374A5 JP 1998506830 A JP1998506830 A JP 1998506830A JP 50683098 A JP50683098 A JP 50683098A JP 2000515374 A5 JP2000515374 A5 JP 2000515374A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998506830A
Other languages
English (en)
Japanese (ja)
Other versions
JP4219985B2 (ja
JP2000515374A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL1997/000438 external-priority patent/WO1998003670A1/en
Publication of JP2000515374A publication Critical patent/JP2000515374A/ja
Publication of JP2000515374A5 publication Critical patent/JP2000515374A5/ja
Application granted granted Critical
Publication of JP4219985B2 publication Critical patent/JP4219985B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP50683098A 1996-07-23 1997-07-23 二つの共刺激経路を同時にブロックできる可溶性分子を用いたt細胞寛容の誘導 Expired - Fee Related JP4219985B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2207096P 1996-07-23 1996-07-23
US60/022,070 1996-07-23
PCT/NL1997/000438 WO1998003670A1 (en) 1996-07-23 1997-07-23 Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways

Publications (3)

Publication Number Publication Date
JP2000515374A JP2000515374A (ja) 2000-11-21
JP2000515374A5 true JP2000515374A5 (https=) 2005-03-10
JP4219985B2 JP4219985B2 (ja) 2009-02-04

Family

ID=21807674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50683098A Expired - Fee Related JP4219985B2 (ja) 1996-07-23 1997-07-23 二つの共刺激経路を同時にブロックできる可溶性分子を用いたt細胞寛容の誘導

Country Status (7)

Country Link
US (1) US20020150559A1 (https=)
EP (1) EP0922111B1 (https=)
JP (1) JP4219985B2 (https=)
AT (1) ATE283925T1 (https=)
CA (1) CA2260752A1 (https=)
DE (1) DE69731836T2 (https=)
WO (1) WO1998003670A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2292415A1 (en) * 1997-06-20 1998-12-30 Innogenetics N.V. B7-binding molecules for treating immune diseases
CA2319448A1 (en) * 1998-02-04 1999-08-12 The General Hospital Corporation Costimulatory blockade and mixed chimerism in allotransplantation
FR2789089A1 (fr) * 1999-02-02 2000-08-04 Pf Medicament Lymphocytes t humains effecteurs exprimant la molecule cd86 et possedant des proprietes immunodulatrices, costimulatrices et cytotoxiques, leurs procedes d'obtention et leurs applications
EP1839674A1 (en) * 1999-10-04 2007-10-03 Novartis Vaccines and Diagnostics, Inc. CD40 antagonist for treating psoriasis
ATE363290T1 (de) * 1999-10-04 2007-06-15 Novartis Vaccines & Diagnostic Cd40 antagonist zur behandlung von psoriasis
WO2002011763A1 (en) * 2000-04-19 2002-02-14 Tanox, Inc. Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US20030059888A1 (en) * 2001-08-22 2003-03-27 Shengfeng Li Compositions and methods for generating antigen-binding units
WO2004076488A1 (en) * 2003-02-27 2004-09-10 Theravision Gmbh A molecule which binds cd80 and cd86
WO2005018668A1 (en) * 2003-08-25 2005-03-03 Pangenetics B.V. Method of inducing immune tolerance
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
HRP20170374T1 (hr) * 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
NZ592420A (en) * 2008-10-02 2012-12-21 Emergent Product Dev Seattle Cd86 antagonist multi-target binding proteins
CN105218673A (zh) * 2008-10-10 2016-01-06 新兴产品开发西雅图有限公司 Tcr复合物免疫治疗剂
SG10201608307WA (en) 2012-04-20 2016-11-29 Emergent Product Dev Seattle Cd3 binding polypeptides
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
CN108136010A (zh) 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法
CN108264561B (zh) * 2016-12-30 2021-09-10 惠和生物技术(上海)有限公司 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU675929B2 (en) * 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
GB9412166D0 (en) * 1993-09-22 1994-08-10 Medical Res Council Retargetting antibodies
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40

Similar Documents

Publication Publication Date Title
JP2000504714A5 (https=)
JP2000515778A5 (https=)
JP2001503254A5 (https=)
JP2000515996A5 (https=)
JP2000507471A5 (https=)
JP2000516515A5 (https=)
JP2000512005A5 (https=)
JP2000503163A5 (https=)
JP2000513648A5 (https=)
JP2000510108A5 (https=)
JP2000505719A5 (https=)
JP2001506735A5 (https=)
JP2001504036A5 (https=)
JP2000509829A5 (https=)
JP2000515510A5 (https=)
JP2001505463A5 (https=)
JP2001503917A5 (https=)
JP2001503601A5 (https=)
JP2000507308A5 (https=)
JP2001505287A5 (https=)
JP2000509067A5 (https=)
JP2000500912A5 (https=)
JP2000506032A5 (https=)
JP2000508665A5 (https=)
JP2000504793A5 (https=)